Potential circulating biomarkers of circulating chemokines CCL5, MIP-1β and HA as for early detection of cirrhosis related to chronic HBV (hepatitis B virus) infection

Abstract

Background Due to no clinical symptoms in the compensated stage of cirrhosis, it is usually diagnosed when decompensated complications occur. In this study, the noninvasive circulating biomarkers for early detection to compensated stage of cirrhosis in patients with chronic HBV (hepatitis B virus) infection was explored. Methods According to the Guideline of Prevention and Treatment of Chronic Hepatitis B (2015 Update), 78 patients with CHB (chronic hepatitis B) were divided into mild group, moderate-to-advanced group, while 73 patients with HBV-related cirrhosis were divided into compensated group and decompensated group. Nineteen cytokines and chemokines, four serum liver fibrosis markers were measured using chemiluminescence. The expression of CCL5 in liver tissue was determined with immunohistochemistry. Results The CCL5 expression level in serum increased in CHB patients with aggravated liver injury and significantly decreased in cirrhosis patients with advanced liver fibrosis. ROC analysis revealed that the serum levels of CCL5, HA and MIP-1β were effective in distinguishing patients with cirrhosis from patients with CHB, especially for CCL5. Increasing serum level of CCL5 in CHB patients was severely associated with disease progression. Conclusions The serum levels of CCL5, HA and MIP-1β maybe used to distinguish cirrhosis from CHB patients, moreover, CCL5 was the most reliable marker. The increasing serum levels of CCL5 were significantly related to disease progression in CHB patients.

Identifying potential biomarkers in hepatitis B virus infection and its response to the antiviral therapy by integrated bioinformatic analysis

“…In a previous study, Hu et al found that CCL5 is a reliable biomarker for predicting liver fibrosis and cirrhosis: the expression of CCL5 in serum and hepatic tissue first increased in CHB patients with ongoing liver injury and then significantly decreased in advanced liver cirrhosis patients. 20 Moreover, CCL5 and its receptor CCR5 have been established with roles in cancer progression and tumour immune evasion mechanisms, including in HCC. 21 , 22 An antagonist of CCL5 was found to ameliorate liver fibrosis and prevent HCC in mouse models, which further strengthened the relationship between CCL5 and liver fibrosis or carcinogenesis.…”

RNA-seq profiling reveals PBMC RNA as a potential biomarker for hepatocellular carcinoma

“…This is primarily due to factors such as delay in or absence of diagnosis 6 – 8 . Candidates for liver cancer are commonly patients with underlying liver diseases, such as hepatitis B virus (HBV) infection and cirrhosis 9 . More than half of sick HCC persons are diagnosed with advanced disease, restricting treatment options.…”

Bioinformatics analysis on multiple Gene Expression Omnibus datasets of the hepatitis B virus infection and its response to the interferon-alpha therapy

“…Additionally, we found that CD74, CCL5, CXCL10 and PTPRC were the 4 common genes in terms of the gene co-expression network. The serum level of CCL5 is a reliable marker that can predict disease progression in chronic hepatitis B patients [51]. The intrahepatic expression of CXCL10 was significantly increased in the HBeAg (+) compared to the HBeAg (−) patients [52].…”